HotPennyStockNews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angelas, CA -- (SBWIRE) -- 02/20/2013 -- Harvest Natural Resources, Inc. (NYSE:HNR) shares dropped 36.90%; announced that the Share Purchase Agreement (SPA) between PT Pertamina (Persero) and HNR Energia B.V., a wholly-owned subsidiary of Harvest, for the purchase of Harvest's interests in Venezuela for $725 million has been terminated as a result of the Government of Indonesia, in its capacity as sole shareholder of PT Pertamina (Persero), voting not to approve the transaction. The SPA, announced on June 21, 2012, had also been subject to, among other things, the approval of the Government of the Bolivarian Republic of Venezuela and a majority of Harvest's stockholders.
Can HNR Jump Again? Find Out Here
Millennial Media (NYSE:MM) shares fell 35.94%; reported Q4 EPS of $0.03, $0.02 better than the analyst estimate of $0.01. Revenue for the quarter came in at $58 million versus the consensus estimate of $62.89 million. Millennial Media sees Q1 2013 revenue of $48-50 million, versus the consensus of $56.41 million. Millennial Media sees FY2013 revenue of $270-280 million, versus the consensus of $286.4 million.
How Should Investors React To MM Now? Find Out Here
Garmin Ltd (NASDAQ:GRMN) gapped open sharply lower Wednesday and has continued to decline. The stock is now down 4.57 at $34.67. Garmin has dropped below support and has set a new low for the year. Garmin Ltd. reported fourth quarter pro forma EPS of $0.68 Wednesday morning, down from $0.96 a year ago. The consensus estimate was for EPS of $0.73. Full year 2013 pro forma EPS is expected to be between $2.30 and $2.40, compared to the consensus estimate of $2.82.
Is GRMN Ready To Move Back To New Highs This Year? Find Out Here
Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares decreased 14.33%; announced today the pricing of an underwritten public offering of 8.0 million common shares, at a public offering price of US$4.00 per common share. Oncolytics Biotech Inc. is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic.
How Should Investors Trade ONCY After The Recent Volatile Moves? Find Out Here
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)